We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.45%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$3.11B
AUM Growth
+$2.21M
Cap. Flow
-$39.8M
Cap. Flow %
-1.28%
Top 10 Hldgs %
35.29%
Holding
188
New
16
Increased
26
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.7M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$32.2M
3
MRNA icon
Moderna
MRNA
+$25.5M
4
DHR icon
Danaher
DHR
+$16.7M
5
RMD icon
ResMed
RMD
+$15.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.3M
2
EXAS
Exact Sciences
EXAS
+$21.5M
3
CTLT
CATALENT, INC.
CTLT
+$19.2M
4
XRAY icon
Dentsply Sirona
XRAY
+$17.1M
5
CI icon
Cigna
CI
+$16.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Real Estate 2.82%
3 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
101
Align Technology
ALGN
$12.3B
$4.9M 0.16%
7,459
– –
STRO icon
102
Sutro Biopharma
STRO
$410M
$4.88M 0.16%
32,785
-7,230
-18% -$1.3M
GTHX
103
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.33M 0.14%
423,869
-200,500
-32% -$2.56M
FATE icon
104
Fate Therapeutics
FATE
$294M
$4.25M 0.14%
72,727
– –
CYTK icon
105
Cytokinetics
CYTK
$10.2B
$4.23M 0.14%
+92,871
New +$3.58M
CRSP icon
106
CRISPR Therapeutics
CRSP
$4.87B
$4.17M 0.13%
55,080
-107,257
-66% -$9.37M
GRTX
107
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$4.12M 0.13%
898,374
– –
MEDP icon
108
Medpace
MEDP
$16.1B
$4.11M 0.13%
18,871
– –
STE icon
109
Steris
STE
$22.5B
$4.06M 0.13%
16,669
– –
AUPH icon
110
Aurinia Pharmaceuticals
AUPH
$1.88B
$3.72M 0.12%
162,599
-90,222
-36% -$2.14M
VECT
111
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$3.71M 0.12%
756,502
– –
TEVA icon
112
Teva Pharmaceuticals
TEVA
$39.7B
$3.68M 0.12%
459,651
-148,000
-24% -$1.34M
PTGX icon
113
Protagonist Therapeutics
PTGX
$8.61B
$3.46M 0.11%
101,037
+14,800
+17% +$468K
HR
114
DELISTED
Healthcare Realty Trust Incorporated
HR
$3.29M 0.11%
104,024
– –
AFMD
115
DELISTED
Affimed
AFMD
$3.23M 0.1%
58,604
– –
XRAY icon
116
Dentsply Sirona
XRAY
$2.81B
$3.2M 0.1%
57,400
-310,121
-84% -$17.1M
XRN
117
Chiron Real Estate Inc
XRN
$514M
$3.1M 0.1%
34,979
– –
TAK icon
118
Takeda Pharmaceutical
TAK
$53.9B
$2.86M 0.09%
210,146
– –
CCXI
119
DELISTED
ChemoCentryx, Inc.
CCXI
$2.85M 0.09%
78,197
– –
ARQT icon
120
Arcutis Biotherapeutics
ARQT
$3.29B
$2.73M 0.09%
131,633
– –
ZLAB icon
121
Zai Lab
ZLAB
$2.07B
$2.72M 0.09%
43,300
+5,777
+15% +$490K
SRRK icon
122
Scholar Rock
SRRK
$5.61B
$2.7M 0.09%
108,833
– –
MREO
123
Mereo BioPharma
MREO
$52.8M
$2.48M 0.08%
1,551,082
– –
MLTX icon
124
MoonLake Immunotherapeutics
MLTX
$1.49B
$2.47M 0.08%
250,000
– –
HR icon
125
Healthcare Realty
HR
$7.17B
$2.36M 0.08%
70,662
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Tekla Capital Management held 188 positions worth $3.11B, up 0.07% from $3.11B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q4 2021 filing shows 16 new, 26 increased, 40 reduced and 17 closed positions. Its largest new stake was AMN Healthcare: 61,201 shares worth $7.49M. The largest sale was Biogen, an estimated $25.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2021 buy was AMN Healthcare: 61,201 shares worth $7.49M.
  • Tekla Capital Management added most to Pfizer in Q4 2021, an estimated $35.7M increase.
  • Tekla Capital Management's biggest Q4 2021 reduction was Biogen, cutting an estimated $25.3M.
  • Tekla Capital Management fully exited Exact Sciences in Q4 2021, selling an estimated $21.5M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $3.11B portfolio in Q4 2021.
  • Tekla Capital Management opened 16 new positions and closed 17 in Q4 2021.
  • Tekla Capital Management's portfolio value rose 0.07% quarter-over-quarter to $3.11B.

Based on Tekla Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.